ow-contrast abdominopelvic CT: compared with image quality and diagnostic performance on high-contrast CT

Gachon University Gil Medical Center0 个研究点目标入组 220 人开始时间: 待定最近更新: 2023年8月1日

试验速览

暂无简介。

•Experimental Group: 1) Cancer patients who obtained informed consent and underwent contrast-enhanced abdominal CT using low-concentration contrast agent (ioversol 270) with a dual-source scanner (CT Force equipment located in the basement of the main building).
•Control Group 1: Retrospective patient group consisting of cancer patients who previously underwent contrast-enhanced abdominal CT using high-concentration contrast agent (ioversol 350) with the dual-source scanner (CT Force equipment located in the basement of the main building). Patients in the control group were matched with patients in the experimental group based on height, weight, and gender using propensity score.

•Exclusion criteria for the study groups were as follows: 1) Cases where the protocol was changed in the performed CT examination. 2) Cases that contraindicate the use of ioversol as indicated in the product manual (1. Patients with known hypersensitivity reactions to this drug, its components, or iodine-containing contrast agents; 2. Patients with severe thyroid disease where iodine may accumulate and worsen symptoms). 3) Other cases where the researchers determined the participant's unsuitability for the clinical trial due to medical reasons, etc. (e.g., Participants with abnormal renal function confirmed by blood tests conducted within one month (serum creatinine exceeding 1.4 mg/dL, estimated glomerular filtration rate (GFR) less than 45 mL/min/1.73 m2). 4) Participants under the age of 20 or over the age of 80

发起方